Business
CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies
Phase 2b trial showed significant improvements on primary and key secondary outcomes measures, most prominently in patients without AD co-pathology Significant reduction in key neurodegeneration biomarker correlated with treatment response, suggesting neflamapimod may act on underlying disease CervoMed preparing to initiate Phase 3 registrational trial in patients with DLB in the second half of 2026 BOSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Today in a late-breaking oral session at the 18th Clini
About this update from Cervomed Inc.
[{"type":"image","alt":"CervoMed Inc.","displaySize":"","headline":null,"caption":"CervoMed Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":93,"url":"https://media.zenfs.com/en/globenewswire.com/59afd81325b0c8128225f052847e0aa6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/YRNF9gHnIhIY0CXM.LMRnA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/59afd81325b0c8128225f052847e0aa6","width":300,"height":93}},"lazy":false},{"type":"text","content":"Phase 2b trial showed significant improvements on primary and key secondary outcomes measures, most prominently in patients without AD co-pathology","length":147,"tagName":"p"},{"type":"text","content":"Significant reduction in key neurodegeneration biomarker correlated with treatment response, suggesting neflamapimod may act on underlying disease ","length":146,"tagName":"p"},{"type":"text","content":"CervoMed preparing to initiate Phase 3 registrational trial in patients with DLB in the second half of 2026","length":108,"tagName":"p"},{"type":"text","content":"BOSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Today in a late-breaking oral session at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference in San Diego, California, clinical investigators shared the full results of the Phase 2b RewinD-LB trial of neflamapimod, being developed by CervoMed Inc. (NASDAQ: CRVO) for the treatment of dementia with Lewy bodies (DLB). In the trial, neflamapimod, which targets the neuroinflammation and synaptic dysfunction that are known to drive DLB disease progression, demonstrated a significant and clinically meaningful effect on multiple outcomes in DLB patients, including on the primary outcome measure, change in CDR sum-of-boxes (CDR-SB). These positive clinical outcomes were correlated with observed reductions in glial fibrillary acidic protein (GFAP), a biomarker of neuronal damage, supporting neflamapimod’s mode of action targeting the underlying mechanism of DLB.","length":924,"tagName":"p"},{"type":"text","content":"“The magnitude of benefit and consistency of data across clinical measures in RewinD-LB provide great confidence that neflamapimod holds true potential to meaningfully slow clinical progression in DLB, a rapidly progressive disease with profound impact on patients and caregivers,” said Dr. John-Paul Tayl...